ArticleParkinson's disease2011
Medication responsiveness of motor symptoms in a population-based study of Parkinson disease.
Article in Parkinson's disease, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- A Self-Administered, Digitized Approach to Quantifying the Cardinal Motor Symptoms in Parkinson's Disease.Sensors (Basel, Switzerland) · 2026Article
- Data-Driven Subtypes of Parkinson Disease Based on Dopamine Responsiveness.CNS neuroscience & therapeutics · 2025Article
- Association analyses of apolipoprotein E genotypes and cognitive performance in patients with Parkinson's disease.European journal of medical research · 2024Article
- Carpets with visual cues can improve gait in Parkinson's disease patients: may be independent of executive function.European journal of medical research · 2023Article
- Gene-wide significant association analyses ofFrontiers in genetics · 2023Article
- Short chain fatty acids-producing and mucin-degrading intestinal bacteria predict the progression of early Parkinson's disease.NPJ Parkinson's disease · 2022Article
- Comparison of Laboratory and Daily-Life Gait Speed Assessment during ON and OFF States in Parkinson's Disease.Sensors (Basel, Switzerland) · 2021Article
- Base-peak assessment of levodopa response and detection of fluctuating patients in Parkinson's disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2020Article
- Association Analyses of Autonomic Dysfunction and Sympathetic Skin Response in Motor Subtypes of Parkinson's Disease.Frontiers in neurology · 2020Article
- Ethnic Variation in the Manifestation of Parkinson's Disease: A Narrative Review.Journal of Parkinson's disease · 2020Review
- Article
- Article
- Cerebrospinal Fluid C-Reactive Protein in Parkinson's Disease: Associations with Motor and Non-motor Symptoms.Neuromolecular medicine · 2018Article
- The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort.Movement disorders : official journal of the Movement Disorder Society · 2016Observational
- Aldehyde dehydrogenase variation enhances effect of pesticides associated with Parkinson disease.Neurology · 2014Article
- Confirmatory factor analysis of the motor unified Parkinson's disease rating scale.Parkinson's disease · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
We assessed degree of Parkinson disease motor symptom improvement with medication among subjects enrolled in an ongoing, population-based study in Central California. The motor section of the unified Parkinson disease rating scale (UPDRS) was performed on subjects in both OFF and ON medication states, and difference between these scores was used as an indicator of symptomatic benefit. Higher OFF minus ON scores correlated with more severe baseline symptoms. There was equivalent improvement on the motor UPDRS scale for subjects divided according to medication classes used: levodopa alone 7.3 points, levodopa plus other medications 8.5 points, and dopamine agonists but not levodopa 6.1 points. In addition, there was no difference in the magnitude of improvement when subjects were divided according to Parkinson disease subtype, defined as tremor dominant, akinetic-rigid, or mixed. In this community-based sample, these values are within the range of a clinically important difference as defined by previous studies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.